Delta-like ligand 4 and tumor treatment / 国际肿瘤学杂志

ABSTRACT

Up-regulation of DLL4 contributes to the angiogenesis in malignant tumors, and thus promote tumor growth. While down-regulation of DLL4 would cause antiangiogenesis and restrain tumor growth through forming a large number of no-function blood vessels. Thus it can be used in anti-VEGF tolerant tumors. Recently, DLL4 monoclonal antibody agents have entered clinic studies, and has achieved good curative effect in anti-VEGF tolerant tumors, but there are also some side effects. DLL4 would bring higher clinic value for cancer therapy if the side effects can be prevented effectively.